Symbiomix Therapeutics

Symbiomix Therapeutics is a private biopharmaceutical company providing anti-infective drugs and single-dose therapies. It is developing innovative drugs for serious women's health infections. The company’s lead product is SYMN-1219, a novel drug candidate containing secnidazole, a next-generation 5-nitroimidazole antibiotic.